
Your Take on “The Selling of Attention Deficit Disorder”?
The controversy around marketing practices for ADHD.
The article that made the front page of the New York Times on December 14th- “
Among the points made:
• Doctors paid by drug companies have published research and delivered presentations that encourage physicians to make diagnoses more often that discredit growing concerns about overdiagnosis.
• Many doctors have portrayed the medications as benign-“safer than aspirin,” some say-even though they can have significant side effects and are regulated in the same class as morphine and oxycodone because of their potential for abuse and addiction.
• The American Psychiatric Association, which receives significant financing from drug companies, has gradually loosened the official criteria for the disorder to include common childhood behavior like “makes careless mistakes” or “often has difficulty waiting his or her turn.”
We’d like to hear from you about the Times' portrayal of ADD therapy and invite you to post your comments below.
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.